ArticleFrontiers in oncology2026
Core needle biopsy as a first-line diagnostic tool for selected thyroid nodules: a real-world evaluation of diagnostic performance and safety.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the diagnostic performance and safety of core needle biopsy (CNB) as a first-line diagnostic tool for selected thyroid nodules with suspicious imaging features or other high-risk characteristics in a real-world setting. Methods: The protocol for this observational study was approved by the Review Board of Tianjin Medical University Cancer Institute and Hospital. All the medical records of patients who underwent ultrasound (US)-guided CNB of thyroid nodules were searched between 1 January 2022 and 30 April 2023. US-guided CNB was performed using a disposable 18-gauge needle, and the pathological results of CNB were divided into six categories: nondiagnostic, benign, indeterminate, follicular neoplasms (FN) or suspected follicular neoplasms (SFN), suspicion of malignancy, and malignancy. The diagnostic performance and complications of CNB and the risk factors associated with inconclusive results were also assessed. Results: A total of 286 patients with 316 nodules were included. Of the 199 cases of malignant nodules, 72 were confirmed by surgery after CNB, and 127 were managed as malignant based on definitive CNB findings in conjunction with clinical and imaging correlation, without surgical confirmation. Among the 78 benign nodules, eight were confirmed by surgery, 50 cases were confirmed by CNB plus contrast-enhanced ultrasound (CEUS), and 20 cases were confirmed by CNB with no change in follow-up for more than 1 year. The non-diagnostic and inconclusive rates were 1.9% and 10.4%, respectively. The diagnostic accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of CNB were 98.2%, 100.0%, 93.6%, 97.5%, and 100.0%, respectively. The rate of unnecessary surgeries was 6.3%. Conclusion: CNB is an effective diagnostic tool for thyroid nodules, demonstrating high diagnostic accuracy and a low rate of non-diagnostic results. It may serve as a viable alternative or complementary first-line diagnostic option for selected nodules, particularly those with suspicious ultrasound features or larger sizes, by providing reliable histological architectural assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.